Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX

Somatic Mutations in <i>UBA1</i> and Severe Adult-Onset Autoinflammatory Disease

David B. Beck, Marcela A. Ferrada, Keith A. Sikora et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*

Sophie Georgin‐Lavialle, Benjamin Terrier, Alexis F. Guédon et al. · British Journal of Dermatology · 2021 · 417 citations · Full text

Medicine, Hematology, Pathology +16

Estimated Prevalence and Clinical Manifestations of <i>UBA1</i> Variants Associated With VEXAS Syndrome in a Clinical Population

David B. Beck, Dale L. Bodian, Vandan Shah et al. · JAMA · 2023 · 233 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Maël Heiblig, Marcela A. Ferrada, Matthew T. Koster et al. · Blood · 2022 · 207 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry

Thibault Comont, Maël Heiblig, Étienne Rivière et al. · British Journal of Haematology · 2021 · 163 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14